Similarly, a recent retrospective cohort study demonstrated that treatment with TNF‐α inhibitors, as well as IL‐12/23, IL‐17, and IL‐23 inhibitors, is associated with a reduced risk of both new‐onset and recurrent MACE in patients with psoriasis [11]. Here, IL17A is linked to psoriasis.